Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ArriVent BioPharma Q3 2026 Results: Net Loss of $40.3M, Loss Widens

ArriVent BioPharma reported collaboration revenue of $5.0 million for the nine months ended September 30, 2026, compared to zero in the prior year. Despite this, the company saw a net loss of $133.5 million driven by $118.9 million in research and development expenses. Cash and short-term investments increased to $393.2 million, bolstered by $199.6 million in net proceeds from common stock issuances.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue5.0—
Net income-40.3-35.0
EPS (diluted, $ a share)$-0.81$-0.83

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AVBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ArriVent BioPharma, Inc.: key numbers

Share price
$10.69Close, Nov 17
Market cap
$553M
Shares outstanding
51.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ArriVent BioPharma, Inc.

All →
4:06 PM ET 8-K
Financial Results

ArriVent BioPharma Financial Results

ArriVent BioPharma reported Q3 2026 financial results, highlighting a cash position of $393.2 million and progress in its Phase 3 ALPACCA study. The company also announced the retirement of Stuart Lutzker, M.D., Ph.D., as President of R&D, with Chief Medical Officer Priti Patel, M.D., assuming leadership of the R&D function.

Term
Q3 2026

“Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies.”

Bing Yao, Ph.D., CEO of ArriVent
6:02 AM ET 8-K
Clinical Trial Data

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.

Counterparty
Lepu Biopharma Co., Ltd.

“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent

“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent
8:08 AM ET 8-K
Clinical Trial Data

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in the journal Cancer Cell, focusing on patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). The data showed a confirmed overall response rate (ORR) of 68% at the 240 mg dose and a median progression-free survival of 16.0 months, supporting the ongoing global Phase 3 ALPACCA trial.

6:03 AM ET 8-K
Business Update

ArriVent BioPharma Business Update

ArriVent BioPharma announced the dosing of the first patient in its U.S. Phase 1 clinical trial of ARR-002, a potential first-in-class dual-target antibody-drug conjugate (ADC). The trial is evaluating the safety and efficacy of the candidate in patients with advanced or metastatic ovarian and endometrial cancer.

8:07 AM ET 8-K
Clinical Trial Data

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review. While the drug showed clinical benefit in secondary endpoints and a consistent safety profile, it failed to show a statistically significant improvement over chemotherapy. The company is currently evaluating the full dataset to determine the future development path for the candidate.

Counterparty
Allist

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.